Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (79)	6/23/1999 5:45:00 AM
From: SnowShredder	Respond to of 319

Peter, Thanks for the link, the author Isner is the one who did the presentation...very interesting stuff. Interestingly, NXTR was working on anti-VEGF in macular degeneration: "NX1838 binds to VEGF[165] with low picomolar affinity, and potently inhibits VEGF-mediated effects both in vitro and in vivo," he said. NXTR...interesting...next thing you know they'll be using it for cancer therapy, too ;) Best of Luck, Where'd He Go?

To: Biomaven who wrote (79)	6/26/1999 9:22:00 PM
From: Walkingshadow	Respond to of 319

WHG, Peter Suzman, and anyone else interested in VEGF gene therapy-- In a recent issue of the journal Circulation (1999;99:3043; text can be obtained via the American Heart Association website under "Scientific Publications", then "Circulation"; I believe it is the June 15 edition), Isner's group reports that in a rabbit hind limb ischemia model, the ACE inhibitor quinaprilat (an oral agent) was as effective as recombinant human VEGF in producing angiogenesis. They conclude: "The results of the present study establish that ACE inhibition with quinaprilat promotes angiogenesis in the rabbit ischemic hindlimb to the same extent as rhVEGF." (pp 3045) Interestingly, another ACE inhibitor, captopril, showed no effect on angiogenesis compared to controls. The authors speculated that the mechanism of quinaprilat-induced angiogenesis is indirect, proceeeding via increased endothelial cell nitric oxide synthesis. They further suggested that the effects of rhVEGF and quinaprilat may be synergistic, although they offered no supporting evidence. No doubt, they are busy testing this hypothesis at the moment. The authors also suggested that the efficacy of ACE inhibitor therapy in treating CHF and, particularly ischemic cardiomyopathies, may be mediated by the angiogenesis-promoting effects of ACE inhibition in the myocardium. The implications of this study are evident: if one can achieve, via a common, relatively inexpensive oral agent the same clinical benefit that VEGF gene therapeutic approaches hope to provide, then the commercial potential of VEGF gene therapy becomes virtually nonexistent, at least for that purpose. I'm sure this potential application is not lost on the manufacturers of the various ACE inhibitors, also. Presently, to the best of my knowledge, they are not prescribed for peripheral vascular disease (an entity that VEGF gene therapy would potentially target), but if clinical data showed a benefit with ACE inhibition, then VEGF would have significant, and perhaps insurmountable competition. Something to consider. Regards, Walkingshadow